Effect of  Limosilactobacillus reuteri  LRE02– Lacticaseibacillus rhamnosus  LR04 Combination on Antibiotic-Associated Diarrhea in a Pediatric Population: A National Survey

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Probiotics are living microorganisms, which, upon oral ingestion, may prevent antibiotic-associated diarrhea (AAD) through the normalization of an unbalanced gastrointestinal flora. The objective of this study was to evaluate the benefits of a probiotic combination ( Limosilactibacillus reuteri LRE02-DSM 23878 and Lacticaseibacillus rhamnosus LR04-DSM 16605) on the prevention of AAD in an outpatient pediatric setting. Questionnaires were delivered to pediatricians by each patient/parent during the visits after antibiotics and probiotics treatment to monitor physiological parameters. The primary outcome of both groups (probiotics and no probiotics treated) was the evaluation of the prevalence of AAD between the two groups. Evaluation of stool consistency using the Bristol Stool Scale (BSS) score was performed, as well as the evaluation of AAD duration, frequencies of daily evacuation, and the beginning of diarrhea and weight loss during AAD in both groups and related to antibiotic categories. Results indicated that probiotics, at the recommended dosage of 1.2 × 10 ⁹ CFU (Colony Forming Unit) per day for 30 days, are associated with lower rates of AAD and a decreased number of days with diarrhea, independent of the type of antibiotic used. Moreover, the use of probiotics resulted in a normal stool consistency in a shorter time period, as evaluated by the BSS.

Related collections

Most cited references 41

Record: found
Abstract: found
Article: not found

A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae

Jinshui Zheng, Stijn Wittouck, Elisa Salvetti … (2020)

The genus Lactobacillus comprises 261 species (at March 2020) that are extremely diverse at phenotypic, ecological and genotypic levels. This study evaluated the taxonomy of Lactobacillaceae and Leuconostocaceae on the basis of whole genome sequences. Parameters that were evaluated included core genome phylogeny, (conserved) pairwise average amino acid identity, clade-specific signature genes, physiological criteria and the ecology of the organisms. Based on this polyphasic approach, we propose reclassification of the genus Lactobacillus into 25 genera including the emended genus Lactobacillus, which includes host-adapted organisms that have been referred to as the Lactobacillus delbrueckii group, Paralactobacillus and 23 novel genera for which the names Holzapfelia, Amylolactobacillus, Bombilactobacillus, Companilactobacillus, Lapidilactobacillus, Agrilactobacillus, Schleiferilactobacillus, Loigolactobacilus, Lacticaseibacillus, Latilactobacillus, Dellaglioa, Liquorilactobacillus, Ligilactobacillus, Lactiplantibacillus, Furfurilactobacillus, Paucilactobacillus, Limosilactobacillus, Fructilactobacillus, Acetilactobacillus, Apilactobacillus, Levilactobacillus, Secundilactobacillus and Lentilactobacillus are proposed. We also propose to emend the description of the family Lactobacillaceae to include all genera that were previously included in families Lactobacillaceae and Leuconostocaceae. The generic term 'lactobacilli' will remain useful to designate all organisms that were classified as Lactobacillaceae until 2020. This reclassification reflects the phylogenetic position of the micro-organisms, and groups lactobacilli into robust clades with shared ecological and metabolic properties, as exemplified for the emended genus Lactobacillus encompassing species adapted to vertebrates (such as Lactobacillus delbrueckii, Lactobacillus iners, Lactobacillus crispatus, Lactobacillus jensensii, Lactobacillus johnsonii and Lactobacillus acidophilus) or invertebrates (such as Lactobacillus apis and Lactobacillus bombicola).

0 comments Cited 861 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

The gut microbiota and host health: a new clinical frontier

Julian Marchesi, David Adams, Francesca Fava … (2015)

Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.

0 comments Cited 483 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Stool form scale as a useful guide to intestinal transit time.

S Lewis, K Heaton (2009)

Stool form scales are a simple method of assessing intestinal transit rate but are not widely used in clinical practice or research, possibly because of the lack of evidence that they are responsive to changes in transit time. We set out to assess the responsiveness of the Bristol stool form scale to change in transit time. Sixty-six volunteers had their whole-gut transit time (WGTT) measured with radiopaque marker pellets and their stools weighed, and they kept a diary of their stool form on a 7-point scale and of their defecatory frequency. WGTT was then altered with senna and loperamide, and the measurements were repeated. The base-line WGTT measurements correlated with defecatory frequency (r = 0.35, P = 0.005) and with stool output (r = -0.41, P = 0.001) but best with stool form (r = -0.54, P < 0.001). When the volunteers took senna (n = 44), the WGTT decreased, whereas defecatory frequency, stool form score, and stool output increased (all, P < 0.001). With loperamide (n = 43) all measurements changed in the opposite direction. Change in WGTT from base line correlated with change in defecatory frequency (r = 0.41, P < 0.001) and with change in stool output (n = -0.54, P < 0.001) but best with change in stool form (r = -0.65, P < 0.001). This study has shown that a stool form scale can be used to monitor change in intestinal function. Such scales have utility in both clinical practice and research.

0 comments Cited 443 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Maria Elisabetta Baldassarre:

ORCID: https://orcid.org/0000-0003-0590-6664

On behalf of : on behalf of the Surveyflor Group †

Journal

Journal ID (nlm-ta): J Clin Med

Journal ID (iso-abbrev): J Clin Med

Journal ID (publisher-id): jcm

Title: Journal of Clinical Medicine

Publisher: MDPI

ISSN (Electronic): 2077-0383

Publication date (Electronic): 24 September 2020

Publication date Collection: October 2020

Volume: 9

Issue: 10

Electronic Location Identifier: 3080

Affiliations

[1 ]Laboratory of Clinical Microbiology and Microbial Metagenomic Unit, Department of Biomedical Sciences, University of Milan, 20133 Milan, Italy; gabriele.meroni@ 123456unimi.it

[2 ]Pediatric Research Center Romeo and Enrica Invernizzi, University of Milan, 20122 Milan, Italy

[3 ]Pediatric Emergency Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS–Rome, 00168 Rome, Italy; achiaretti@ 123456yahoo.it

[4 ]Department of Biomedical Science and Human Oncology-Section of Neonatology and NICU, University “Aldo Moro” of Bari, 70124 Bari, Italy; nicola.laforgia@ 123456uniba.it (N.L.); mariaelisabetta.baldassarre@ 123456uniba.it (M.E.B.)

[5 ]Pediatric Gastroenterology and Liver Unit, Department of Women’s and Children’s Health, Sapienza University of Rome, 00161 Rome, Italy; salvatore.cucchiara@ 123456uniroma1.it

Author notes

[* ]Correspondence: lorenzo.drago@ 123456unimi.it

[†]

Suveyflor Group: Petitti Maria Teresa, Galante Teresa, Lanza Cosimo, Ferrazzano Vincenzo, Romeo Antonio, Bragho’ Salvatore, Nigro Adele, Lippolis Esterina, Amoroso Riccardo, Cimmino Luigi, De Giovanni Maria, Buonavolontà Roberta, Vallini Monica, Paletta Isabella, Rosetti Valentina, Tarchini Guillermo Luis, Riosa Rita, Ortore Massimiliano, Demelas Francesca, Falletta Salvatore, Panocchi Luigi, Bruschi Raffaella, Bitti Stefania, Pedroni Livio, Spinelli Bruno, Clemente Ignazio Alessandro, Carluccio Giovanni Pio, Volpe Cristina Stella Luigia, Garavaglia Mariacarla, Todeschini Michela, Budassi Roberto, Tonelli Gabriele, Costabello Laura, Rosso Paolo, Gallo Annino, Praitano Massimiliano, Caponio Marina Grazia, Truppa Guglielmina, Fazzi Ivan, Pedaci Ferdinando, Di Tonno Patrizia, Moi Mario, Mostallino Basilio, Salamone Pietro, Catalano Rita, Crea Gianfranco, Gatto Silvana, Di Stefano Rosalia, Parinisi Maria Antonietta, Ditta Maria Saida, Faraci Marco, Di Stefano Michelina, Aurnia Pietro, Di Raimondo Santa, Di Pasquale Elisabetta, Clemente Peppino, Ferri Francesca Donatella, Provenzano Giuseppe, Fiore Rosalba Filomena, Monaco Francesca, Di Stefano Gianni, Canella Vanna, Bortolin Claudia, Piovan Sabrina, Cali’ Laura, Esposito Giorgio, Bertorelle Daniela, Cupido Francesco.

Author information

Lorenzo Drago https://orcid.org/0000-0002-5206-540X

Gabriele Meroni https://orcid.org/0000-0003-2772-6410

Antonio Chiaretti https://orcid.org/0000-0002-9971-1640

Nicola Laforgia https://orcid.org/0000-0002-4610-1216

Maria Elisabetta Baldassarre https://orcid.org/0000-0003-0590-6664

Article

Publisher ID: jcm-09-03080

DOI: 10.3390/jcm9103080

PMC ID: 7650601

PubMed ID: 32987822

SO-VID: 2f7bacf0-b9b8-4225-9b28-ee0b1a44a90b

License:

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

Effect of Limosilactobacillus reuteri LRE02– Lacticaseibacillus rhamnosus LR04 Combination on Antibiotic-Associated Diarrhea in a Pediatric Population: A National Survey

Read this article at

Abstract

Related collections

Wits Journal of Clinical Medicine

Most cited references 41

A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae

The gut microbiota and host health: a new clinical frontier

Stool form scale as a useful guide to intestinal transit time.

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Categories

Comments

Comment on this article

Similar content 270

Cited by 4

Most referenced authors 478